The 7th World Congress on Controversies in Multiple Myeloma (COMy) will be held virtually on 7 – 9 May 2021. Leading doctors in myeloma and AL amyloidosis will discuss the latest advances in the field and improvements in patient care.
CAR-T-cell treatment is thought to be one of the most promising therapies in development for the treatment of myeloma. There are several ongoing clinical trials evaluating the safety and efficacy of CAR-T-cells, and some of the studies with very encouraging results.
Myeloma Patients Europe (MPE) held a webinar on ASH 2020 myeloma and AL amyloidosis highlights on 16 November to review the most recent myeloma research presented at the annual meeting of the American Society of Hematology (ASH) 2020 (5 – 8 December 2020).
Myeloma Patients Europe interviewed Dr Giampaolo Merlini, the Research Director and AL amyloidosis expert from Policlinico San Matteo, University of Pavia, in Italy, to summarise the main highlights on this disease presented at the American Society of Hematology (ASH) Annual Meeting. Click to hear a summary of the most important studies presented at ASH 2020 and his views on the future of AL amyloidosis treatment.
The largest haematology meeting in the calendar year, the American Society of Hematology (ASH) Annual Meeting, was held virtually from 5 to 8 December 2020.
Data on real-world efficacy outcomes for 2000 Patients with AL amyloidosis was presented at this year’s American Society of Haematology Annual Meeting (ASH). ASH was held virtually from 5 to 8 December.
There are now millions of cases worldwide of COVID-19 infection. As cases continue to soar, researchers around the globe are working urgently to identify risk factors and possible treatments.
ASH 2020 | The phase III trial Apollo supports administering daratumumab subcutaneously instead of intravenously in relapsed or refractory myeloma patients
A new study suggests the monoclonal antibody daratumumab has similar benefits when delivered via subcutaneous injection as it does when delivered intravenously to patients which myeloma persists or recurs after first-line treatments. Patients given subcutaneous daratumumab along with the immunomodulator pomalidomide and the anti-inflammatory steroid dexamethasone were 37% less likely to die or have their disease worsen compared to patients who received pomalidomide and dexamethasone alone in the phase III trial.
Myeloma Patients Europe (MPE), in collaboration with the pharmaceutical company Amgen, launched a survey in 2019 for European myeloma patients to understand their treatment information needs.